Navigation Links
CEL-SCI Expands H1N1 Flu Virus Work
Date:8/18/2009

VIENNA, Va., Aug. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), announces that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality. The new work will add regions of the hemagglutinin molecule which are highly conserved and essential for the virus' survival. This work comes on top of the ongoing work being conducted against other non-changing parts of the virus. CEL-SCI scientists believe that the combination of various non-changing regions on the virus in one treatment or vaccine will allow for a greater ability to treat and protect against the current H1N1 virus and any possible future mutation.

CEL-SCI has two on-going research programs directed towards the H1N1 virus. The first one is directed against a future mutated form of the virus. It is the fear of many experts that the H1N1 virus will continue to mutate and "swap genes" to become more lethal. CEL-SCI is focused on creating a treatment/vaccine against such a virus by combining non-changing parts of the H1N1 virus, the Avian Flu virus and the Spanish Flu virus. When a new virus surfaces, this treatment/vaccine is expected to provide an important cornerstone for the fight against the virus.

The second program is directed at helping very sick patients infected with the current form of H1N1. CEL-SCI expects to give updated communication on that program within the next month.

CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against a specific disease epitope, in this case non-changing regions of H1N1, Avian Flu and the Spanish Flu. This makes it possible to 1) program the intended immune response and 2) avoid the administration of regions of the H1N1, and other viruses, that may exacerbate the problem of cytokine storm. Cytokine storm is very much involved in the death of many H1N1 patients.

The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin molecule, to make a vaccine that induces a defined immune response. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models. In CEL-SCI's L.E.A.P.S. swine flu vaccine the TCBLs will be coupled to three different highly conserved protective epitopes from three different essential proteins common to all influenza A virus strains.

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
2. CEL-SCI Posts New Corporate Presentation to Website
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
6. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
7. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
8. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. CEL-SCI Corporation Announces 2007 Financial Results
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CITY , March 29, 2017  Bodycad ... and Drug Administration (FDA) 510(k) clearance for its ... of this truly personalized orthopaedic restoration. Bodycad is ... for a joint reconstruction implant system. ... to optimize personalized restoration of the patient,s unique ...
(Date:3/29/2017)... Global intravenous (IV) iron and oral iron market ... at a CAGR of 5%. Iron drugs ... treat anemia or other iron deficiencies. Oral iron supplements are ... in some cases, oral administrations are not capable of maintaining ... therapy comes into the picture. Global Intravenous (IV) ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare partner ... with prominent executives from both inside and outside the cannabis industry. , Joining ... , who has more than twenty years of business leadership and investment experience in ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
Breaking Medicine News(10 mins):